CY1126036T1 - Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας - Google Patents

Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας

Info

Publication number
CY1126036T1
CY1126036T1 CY20231100265T CY231100265T CY1126036T1 CY 1126036 T1 CY1126036 T1 CY 1126036T1 CY 20231100265 T CY20231100265 T CY 20231100265T CY 231100265 T CY231100265 T CY 231100265T CY 1126036 T1 CY1126036 T1 CY 1126036T1
Authority
CY
Cyprus
Prior art keywords
sacubitril
valsartan
heart failure
dosage forms
therapeutic treatment
Prior art date
Application number
CY20231100265T
Other languages
English (en)
Inventor
Adel Redmond RIZKALA
Fabian CHEN
Victor Chengwei Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55967342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126036(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1126036T1 publication Critical patent/CY1126036T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με δοσολογικά σχήματα σακουμπιτρίλης-βαλσαρτλανης για τη θεραπευτική αντιμετώπιση της καρδιακής ανεπάρκειας σε έναν ασθενή.
CY20231100265T 2015-05-11 2023-06-02 Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας CY1126036T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159703P 2015-05-11 2015-05-11
PCT/IB2016/052633 WO2016181284A1 (en) 2015-05-11 2016-05-09 Sacubitril-valsartan dosage regimen for treating heart failure

Publications (1)

Publication Number Publication Date
CY1126036T1 true CY1126036T1 (el) 2023-11-15

Family

ID=55967342

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100265T CY1126036T1 (el) 2015-05-11 2023-06-02 Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας

Country Status (15)

Country Link
US (2) US11058667B2 (el)
EP (2) EP4212152A1 (el)
JP (1) JP6576469B2 (el)
CY (1) CY1126036T1 (el)
DK (1) DK3294283T3 (el)
ES (1) ES2945866T3 (el)
FI (1) FI3294283T3 (el)
HR (1) HRP20230480T1 (el)
HU (1) HUE062195T2 (el)
LT (1) LT3294283T (el)
PL (1) PL3294283T3 (el)
PT (1) PT3294283T (el)
RS (1) RS64242B1 (el)
SI (1) SI3294283T1 (el)
WO (1) WO2016181284A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576469B2 (ja) 2015-05-11 2019-09-18 ノバルティス アーゲー 心不全の治療のためのサクビトリル−バルサルタンの用量計画
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US20220395491A1 (en) * 2019-09-20 2022-12-15 Shenzhen Salubris Pharmaceuticals Co. Ltd Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure
WO2021230664A1 (ko) * 2020-05-12 2021-11-18 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
BRPI0306907B8 (pt) 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
SI3067043T1 (sl) 2007-11-06 2023-04-28 Novartis Ag Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
AU2013304949C1 (en) 2012-08-24 2020-12-24 Novartis Ag NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling
US20160206597A1 (en) 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
JP6576469B2 (ja) 2015-05-11 2019-09-18 ノバルティス アーゲー 心不全の治療のためのサクビトリル−バルサルタンの用量計画

Also Published As

Publication number Publication date
US20220133694A1 (en) 2022-05-05
LT3294283T (lt) 2023-06-12
HUE062195T2 (hu) 2023-10-28
JP2018519266A (ja) 2018-07-19
EP4212152A1 (en) 2023-07-19
PL3294283T3 (pl) 2023-07-24
RS64242B1 (sr) 2023-06-30
PT3294283T (pt) 2023-06-07
JP6576469B2 (ja) 2019-09-18
SI3294283T1 (sl) 2023-07-31
HRP20230480T1 (hr) 2023-07-21
US20180125820A1 (en) 2018-05-10
FI3294283T3 (fi) 2023-05-24
WO2016181284A1 (en) 2016-11-17
DK3294283T3 (da) 2023-05-30
ES2945866T3 (es) 2023-07-10
US11058667B2 (en) 2021-07-13
EP3294283B1 (en) 2023-03-08
EP3294283A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
CY1126036T1 (el) Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
DK3289080T3 (da) Genterapi til autosomalt dominante sygdomme
DK3360508T3 (da) Hjælpeanordning til dental behandling
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3328880T3 (da) Terapeutiske midler
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
DK3171929T3 (da) Dosering til nervestimulation
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
KR20180084772A (ko) 암 치료를 위한 조합 치료법
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
CY1124759T1 (el) Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler